Skip to search formSkip to main contentSkip to account menu

Botulinum Toxin Type A

Known as: Clostridium Botulinum Toxin Type A, BoNT/A, Botulinum Toxins, Type A 
An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular… 
National Institutes of Health

Related topics

Related topics

42 relations
Anal FissureBlepharospasmBotulinum Toxin Type A InjectionClostridium botulinum toxin A Ab:PrThr:Pt:Ser:Ord

Narrower (13)

BotoxDWP450DysportHengli BTX-A

Broader (3)

Botulinum ToxinsNeuromuscular AgentsNeurotoxins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Advances in Facial Rejuvenation: Botulinum Toxin Type A, Hyaluronic Acid Dermal Fillers, and Combination Therapies–-Consensus Recommendations
Background: Facial aesthetics and rejuvenation are evolving rapidly due to changes in products, procedures, and patient… 
Highly Cited
2004
Highly Cited
2004
Regulation of Calcitonin Gene‐Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy
Objective.—To determine the effect of botulinum toxin type A on calcitonin gene‐related peptide secretion from cultured… 
Review
2004
Review
2004
Consensus recommendations on the use of botulinum toxin type a in facial aesthetics.
The use of botulinum toxin type A for facial enhancement is the most common cosmetic procedure currently undertaken in the United… 
Review
2003
Review
2003
Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management
  • K. Aoki
  • Headache
  • 2003
  • Corpus ID: 36296594
The neurotoxin, botulinum toxin type A, has been used successfully, in some patients, as an analgesic for myofascial pain… 
Highly Cited
2000
Highly Cited
2000
Botulinum Toxin Type A as a Migraine Preventive Treatment
Objective.—To assess the safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Inc) in the prevention of migraine. 
Highly Cited
1999
Highly Cited
1999
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
Blockade of acetylcholine release by botulinum neurotoxin type A at the neuromuscular junction induces the formation of an… 
Highly Cited
1998
Highly Cited
1998
Crystal structure of botulinum neurotoxin type A and implications for toxicity
Botulinum neurotoxin type A (BoNT/A) is the potent disease agent in botulism, a potential biological weapon and an effective… 
Review
1994
Review
1994
Development of resistance to botulinum toxin type A in patients with torticollis
Between 1984 and 1992, 559 patients with torticollis were treated with botulinum toxin type A (btx) injections. Twenty‐four of… 
Highly Cited
1993
Highly Cited
1993
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
NEUROTRANSMITTER release is potently blocked by a group of structurally related toxin proteins produced by Clostridium botulinum1… 
Review
1991
Review
1991
Therapeutic uses of botulinum toxin.
BOTULISM had been recognized by the 18th century, but the observation that a toxin produced by an anaerobic organism might be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License